Heterozygous disruption of activin receptor-like kinase 1 is associated with increased arterial pressure in mice

Dis Model Mech. 2015 Nov;8(11):1427-39. doi: 10.1242/dmm.019695. Epub 2015 Sep 17.

Abstract

The activin receptor-like kinase 1 (ALK-1) is a type I cell-surface receptor for the transforming growth factor-β (TGF-β) family of proteins. Hypertension is related to TGF-β1, because increased TGF-β1 expression is correlated with an elevation in arterial pressure (AP) and TGF-β expression is upregulated by the renin-angiotensin-aldosterone system. The purpose of this study was to assess the role of ALK-1 in regulation of AP using Alk1 haploinsufficient mice (Alk1(+/-)). We observed that systolic and diastolic AP were significantly higher in Alk1(+/-) than in Alk1(+/+) mice, and all functional and structural cardiac parameters (echocardiography and electrocardiography) were similar in both groups. Alk1(+/-) mice showed alterations in the circadian rhythm of AP, with higher AP than Alk1(+/+) mice during most of the light period. Higher AP in Alk1(+/-) mice is not a result of a reduction in the NO-dependent vasodilator response or of overactivation of the peripheral renin-angiotensin system. However, intracerebroventricular administration of losartan had a hypotensive effect in Alk1(+/-) and not in Alk1(+/+) mice. Alk1(+/-) mice showed a greater hypotensive response to the β-adrenergic antagonist atenolol and higher concentrations of epinephrine and norepinephrine in plasma than Alk1(+/+) mice. The number of brain cholinergic neurons in the anterior basal forebrain was reduced in Alk1(+/-) mice. Thus, we concluded that the ALK-1 receptor is involved in the control of AP, and the high AP of Alk1(+/-) mice is explained mainly by the sympathetic overactivation shown by these animals, which is probably related to the decreased number of cholinergic neurons.

Keywords: Activin receptor-like kinase 1; Angiotensin II; Animal model of human disease; Arterial pressure; Catecholamines; Intracerebroventricular injection; Nitric oxide; Sympathetic nervous system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activin Receptors, Type I / deficiency*
  • Activin Receptors, Type I / genetics
  • Activin Receptors, Type II
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Arterial Pressure* / drug effects
  • Arterial Pressure* / genetics
  • Central Nervous System / pathology
  • Central Nervous System / physiopathology
  • Cholinergic Neurons / pathology
  • Circadian Rhythm
  • Dose-Response Relationship, Drug
  • Genetic Predisposition to Disease
  • Haploinsufficiency
  • Heterozygote*
  • Hypertension / drug therapy
  • Hypertension / enzymology*
  • Hypertension / genetics
  • Hypertension / pathology
  • Hypertension / physiopathology
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Phenotype
  • Renin-Angiotensin System / drug effects
  • Sympathetic Nervous System / enzymology
  • Sympathetic Nervous System / physiopathology
  • Time Factors
  • Vasoconstriction / drug effects
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation / drug effects
  • Vasodilator Agents / pharmacology

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Activin Receptors, Type I
  • Activin Receptors, Type II
  • Acvrl1 protein, mouse